Benzinga | Jan 31, 2022 08:07AM EST

ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up



* Manufactured IMX-110 to be utilized in both clinical trials:

* 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma ("STS")

* 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors

An image of IMX-110 is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/870f17c2-db33-4a8b-bccd-b09dc60f1e7d.

LOS ANGELES, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (NASDAQ:IMMX) ("ImmixBio", "Company", "We" or "Us"), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that it has initiated IMX-110 Good Manufacturing Practice ("GMP") scale-up manufacturing, potentially accelerating the timeline to clinical data from two ImmixBio clinical trials planned for 2022: first, planned monotherapy IMX-110 clinical trial in soft tissue sarcoma ("STS"); second, planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab clinical trial in advanced solid tumors.

"Initiating GMP manufacturing 36 days after the closing of our IPO puts us on a path of potentially accelerating our clinical trials," said Ilya Rachman, MD PhD, CEO of ImmixBio. "We believe this step paves the way to execute our planned milestones at an accelerated pace."